

# 48<sup>th</sup> Annual Robert B. Aird Visiting Professor of Neurology

## *New Insights and Approaches for ALS Therapy Development*



### Merit Cudkowicz, MD, MSc

Chief, Department of Neurology  
Director, Sean M. Healey & AMG Center for ALS  
Massachusetts General Hospital  
Julianne Dorn Professor of Neurology, Harvard Medical School

Dr. Cudkowicz's research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). Dr. Cudkowicz is one of the founders and past co-chairs of the Northeast ALS Consortium (NEALS), a group of over 134 clinical sites performing collaborative clinical trials and research in ALS. She has brought innovations to accelerate the development of treatments for people with ALS, including her senior role in the first antisense oligonucleotide treatment for a neurological disorder (SOD1 ALS) and adaptive trial designs. Dr. Cudkowicz is PI of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke's Neurology Network of Excellence in Clinical Trials (NeuroNEXT). She is launching the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that will greatly accelerate therapy development in ALS.

*At the end of the presentation, attendees will better understand:*

1. ALS biology and therapy targets.
2. New treatments for ALS.
3. New trial approaches in ALS.

Wednesday, October 21, 2020 | 5:00 – 7:00pm  
Zoom Webinar - Link TBA